Evercore ISI Group Maintains Outperform on TG Therapeutics, Lowers Price Target to $71

Benzinga · 2d ago
Evercore ISI Group analyst Michael DiFiore maintains TG Therapeutics (NASDAQ:TGTX) with a Outperform and lowers the price target from $73 to $71.